Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of Hemispherx Biopharma of Upcoming Deadline -- HEB

Troy Schwensen February 15, 2013

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of Hemispherx Biopharma of Upcoming Deadline -- HEB

Troy Schwensen February 8, 2013

Levi & Korsinsky Notifies Investors With Losses on Their Investment in Hemispherx Biopharma, Inc. of Class Action Lawsuit and the Deadline of March 5, 2013 to Seek a Lead Plaintiff Position

Marketwired February 6, 2013

Free Research Reports on BIDU, HEB, IDIX and YUM Issued by the Bedford Report

Marketwired February 6, 2013

Cohen Milstein Sellers & Toll PLLC Continues to Investigate Hemispherx Biopharma, Inc. Following the FDA's Rejection of the Ampligen New Drug Application

Business Wire February 5, 2013

Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome

Troy Schwensen February 4, 2013

Rosen Law Firm Reminds Hemispherx Biopharma, Inc. Investors of Important February 22, 2013 Deadline -- HEB

Troy Schwensen February 1, 2013

Biotech Companies Attractive Targets for Pharma Companies Looking to Replace Lost Revenues

Marketwired February 1, 2013

Free Research Reports on ABIO, ANX, HEB and ISIS Issued by the Bedford Report

Marketwired January 31, 2013

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of Hemispherx Biopharma of Upcoming Deadline - HEB

Troy Schwensen January 25, 2013

Pittsburgh Law Office of Alfred G. Yates Jr., P.C. Files Class Action Lawsuit On Behalf of Shareholders of Groupon (GRPN) and Announces Investigations of Diodes (DIOD), Hemispherex Biopharma (HEB), ISIS Pharmaceuticals (ISIS), K-Swiss (KSWS), MAP Pharmaceuticals (MAPP), Neptune Technologies & Bioressources (NEPT), SeaCube Container Leasing (BOX), Spirit AeroSystems Holdings (SPR), Verisign (VRSN), and Yum! Brands (YUM)

PR Newswire January 23, 2013

Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.

PR Newswire January 17, 2013

Levi & Korsinsky Notifies Investors With Losses on Their Investment in Hemispherix Biopharma, Inc. of Class Action Lawsuit and the Deadline of March 5, 2013 to Seek a Lead Plaintiff Position -- HEB

Troy Schwensen January 17, 2013

Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Hemispherx Biopharma, Inc.

Business Wire January 16, 2013

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of Hemispherx Biopharma of Upcoming Deadline -- HEB

Troy Schwensen January 11, 2013

Rosen Law Firm Reminds Hemispherx Biopharma, Inc. Investors of Important Class Action Deadline -- HEB

Troy Schwensen January 4, 2013

Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Hemispherx Biopharma, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the February 22, 2013 Lead Plaintiff Deadline -- HEB

Troy Schwensen January 4, 2013

Faruqi & Faruqi, LLP Encourages Investors Who Suffered $50,000 or More In Losses Investing In Hemispherx Biopharma, Inc. To Contact The Firm

PR Newswire December 28, 2012

Gainey & McKenna Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Hemispherx Biopharma, Inc. -- HEB

Troy Schwensen December 28, 2012

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Hemispherx Biopharma, Inc.

PR Newswire December 28, 2012